{"id":"W4412461073","doi":"10.1016/s1470-2045(25)00330-4","title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Refractory (planetary science); Open label; Oncology; Internal medicine; Lenalidomide; Clinical trial; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002836487,0.001159526,0.003104876,0.0004374818,0.0002715538,0.00125189,0.0009660522,0.001057876,0.00339711],"category_scores_gemma":[0.001653766,0.0004749156,0.003268839,0.0004275179,0.001073776,0.001690425,0.0006460004,0.00391331,0.0007687155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001225907,"about_ca_system_score_gemma":0.001045182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001139793,"about_ca_topic_score_gemma":0.00375094,"domain_scores_codex":[0.9990022,0.0006045276,0.00005295863,0.0001244293,0.00008792383,0.0001279967],"domain_scores_gemma":[0.9991203,0.0002969117,0.0002190918,0.00006760894,0.00005429506,0.000241795],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9181183,0.002173001,0.001473483,0.001802792,0.005148927,0.00004472459,0.0001038398,0.001197983,0.00251146,0.0003670088,0.002769836,0.06428865],"study_design_scores_gemma":[0.9352407,0.05339593,0.004278814,0.0001688129,0.002165062,0.0001266336,0.00007677035,0.0006911131,0.000412686,0.0005977217,0.002809726,0.0000359611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9491863,0.03978373,0.0008590591,0.002083738,0.001030969,0.001084896,0.00191349,0.0001948809,0.003862893],"genre_scores_gemma":[0.9762797,0.01276787,0.001879845,0.002216005,0.0004510006,0.001085212,0.002638418,0.00004850471,0.002633501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00339711,"threshold_uncertainty_score":0.01500094,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06159927844167269,"score_gpt":0.3929654672770072,"score_spread":0.3313661888353345,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}